Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Dig Dis Sci. 2008 May;53(5):1417-21. doi: 10.1007/s10620-008-0235-9. Epub 2008 Mar 18.

CYP1B1 polymorphisms and k-ras mutations in patients with pancreatic ductal adenocarcinoma.

Author information

  • 1Institut Municipal d'Investigació Mèdica (IMIM), CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Abstract

The frequency of CYP1B1 polymorphisms in pancreatic cancer has never been reported. There is also no evidence on the relationship between CYP1B1 variants and mutations in ras genes (K-, H- or N-ras) in any human neoplasm. We analyzed the following CYP1B1 polymorphisms in 129 incident cases of pancreatic ductal adenocarcinoma (PDA): the m1 allele (Val to Leu at codon 432) and the m2 allele (Asn to Ser at codon 453). The calculated frequencies for the m1 Val and m2 Asn alleles were 0.45 and 0.68, respectively. CYP1B1 genotypes were out of Hardy-Weinberg equilibrium; this was largely due to K-ras mutated PDA cases. The Val/Val genotype was over five times more frequent in PDA cases with a K-ras mutation than in wild-type cases (OR = 5.25; P = 0.121). In PDA, polymorphisms in CYP1B1 might be related with K-ras activation pathways.

PMID:
18347981
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk